Alnylam Pharmaceuticals (ALNY) Finished Goods (2018 - 2026)

Alnylam Pharmaceuticals' Finished Goods history runs 9 years deep, the most recent figure standing at $39.0 million for Q1 2026.

• Quarterly Finished Goods rose 18.25% year-over-year to $39.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.0 million (up 18.25% YoY) and the FY2025 annual result came in at $32.3 million, up 22.34% from the prior year.
• Finished Goods was $39.0 million for Q1 2026 at Alnylam Pharmaceuticals, up from $32.3 million in the prior quarter.
• Across five years, Finished Goods topped out at $39.0 million in Q1 2026 and bottomed at $10.4 million in Q1 2022.
• A 5-year average of $27.1 million and a median of $27.7 million in 2023 frame the typical range for Finished Goods.
• Peak annual rise in Finished Goods reached 265.54% in 2022, while the deepest fall reached 24.18% in 2022.
• Alnylam Pharmaceuticals' Finished Goods stood at $25.6 million in 2022, then dropped by 1.89% to $25.1 million in 2023, then increased by 5.21% to $26.4 million in 2024, then increased by 22.34% to $32.3 million in 2025, then increased by 20.54% to $39.0 million in 2026.
• Business Quant data shows ALNY's Finished Goods at $39.0 million in Q1 2026, $32.3 million in Q4 2025, and $38.8 million in Q3 2025.